- |||||||||| ST-502 / Biogen
Retrospective data, Journal: Multidrug-resistant Klebsiella pneumoniae: a retrospective study in Manaus, Brazil. (Pubmed Central) - Mar 11, 2022 MLST analysis demonstrated a great diversity of STs among the strains, totaling 12 different STs (ST11, ST23, ST198, ST277, ST307, ST340, ST378, ST462, ST502, ST3991, ST3993 and ST5209). Three of these (ST11, ST23 and ST340) belong to CG258.
- |||||||||| Vynfinit (vintafolide) / Novartis
Journal: Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent. (Pubmed Central) - Jan 14, 2021 When evaluated against FR-positive patient derived xenograft (PDX) models of ovarian (ST070), endometrial (ST040) and triple negative breast cancers (ST502, ST738), EC2629 showed significantly greater anti-tumor activity compared to their corresponding standard of care treatments. Taken together, these studies thus demonstrated that EC2629, with its distinct DNA reacting mechanism, may be useful in treating FR-positive tumors, including those that are classified as drug resistant.
- |||||||||| ST-502 / Biogen
Clinical, Journal: Whole-Genome-Sequence-Based Characterization of Extensively Drug-Resistant Acinetobacter baumannii Hospital Outbreak. (Pubmed Central) - Oct 22, 2020 Genome analysis initially revealed two clones, one carrying bla on Tn2006 (ST-1305, ST-195, and ST-218) and another carrying bla on pMAL-1 (ST-502 and ST-2059, a new ST), with the latter having two subclones, as revealed using the Bayesian transmission network...A pMAL-2 plasmid was circulating between the two clones. The approaches implemented in this study and the obtained findings facilitate the tracking of outbreak scenarios in Lebanon and the region at large.
|